Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

U033 - An Evidenced-Based Approach to Morbilliform Eruptions in a Patient Who Has Not Had Stem Cell Transplant

Saturday, February 17; 7:30 AM - 8:30 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Differentiate the severe cutaneous adverse reactions from typical morbilliform presentations
  • Distinguish viral vs drug etiologies based on locations, minor-morphologies, and associated findings
  • Identify the common causes of drug-induced morbilliform eruptions and have a procedure to rapidly assess likelihood


The morbilliform eruption is the most common cutaneous morphology seen in the hospital setting. This session will address a method to identify the etiology. We will review features that allow for early identification of severe cutaneous adverse reactions, and then differentiate the common drug and viral etiologies.


  • Kaffenberger, Benjamin, MD: Biogen – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Dermatology Foundation – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); National Rosacea Society – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – I(Grants/Research Funding); Veloce BioPharma LLC – I(Grants/Research Funding); XBiotech – I(Grants/Research Funding);
Saturday, February 17
7:30 AM
Dr. Kaffenberger / An Evidenced-Based Approach to Morbilliform Eruptions
Event Details
  • Date
    Saturday, February 17
  • Time
    7:30 AM - 8:30 AM
  • Location
    Room 2
  • CME Credits
  • Type